Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 9, 1999

View Archived Issues

New antiviral agents from SB for herpesvirus infections

Avigen granted U.S. patent for TVI gene therapy

Hughes Institute enters licensing agreement for anticancer drug development

Discovery's Surfaxin shows positive phase II results in MAS

IOCM approves Rebif for MS

Positive results reported for Ergoset in insulin-treated type II diabetics

Enrollment completed in Maxim's malginant melanoma phase III trial

NIH seeks licensees and/or CRADA partners for development of HCV vaccine

Novel gene delivery system available for licensing from NIH

Antiallergic/antiasthmatic agents from Kaken acting specifically on eosinophils

PKC inhibitors designed at Otsuka

New photoactive agents in development at QLT and U. of British Columbia

Adjuvants and immunoeffectors from AGP series under evaluation at Ribi

Nonpeptide GnRH antagonists claimed by Merck & Co.

Oxazolidinones from P&U with broad-spectrum antibacterial activity

NIH researchers determine 3-D structure of melatonin enzyme

Animal study supports cognition-enhancing efficacy of nefiracetam following ischemia

Clot-dissolving drug significantly improves disability outcome in phase III stroke trial

Abciximab undergoing clinical evaluation in acute ischemic stroke

Neuroprotective effects of FK-506 in rat stroke model not mediated by suppression of NO production

Status update for OPB-2045

Britannia seeks new owner to take the helm for a new era

Metabolism of potent new progestagen examined in vitro and in vivo

Byk Gulden's roflumilast in clinical trials; spotlight on PDE4 inhibitors for asthma

Picroliv now reported to possess promising antiallergic activity

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 20, 2026.
Biohaven reports details on discovery of BHV-2100
BioWorld Science
Transient receptor potential melastatin 3 (TRPM3) is a calcium-permeable TRP channel that is highly expressed in somatosensory neurons, including nociceptors of...
Meta-analysis: Anti-amyloid Alzheimer’s drugs not ‘clinically meaningful’
BioWorld
The ongoing controversy over the effectiveness of anti-amyloid drugs is about to get more heated, after a review of clinical trials showed statistically...
New GABA(B) receptor PAMs revealed in Addex Pharma patents
BioWorld Science
Addex Pharma SA has disclosed new GABA(B) receptor positive allosteric modulators (PAMs) potentially useful for the treatment of chronic cough, urinary...
Novel caspase-2 inhibitor shows in vivo neuroprotective effects
BioWorld Science
Caspase-2-mediated cleavage of tau at Asp314 generates a neurotoxic fragment, Δtau314, that drives early synaptic dysfunction in Alzheimer’s disease (AD) and...